119 related articles for article (PubMed ID: 10803125)
1. CA 15-3 and c-erbB-2 presence in the saliva of women.
Streckfus C; Bigler L; Dellinger T; Pfeifer M; Rose A; Thigpen JT
Clin Oral Investig; 1999 Sep; 3(3):138-43. PubMed ID: 10803125
[TBL] [Abstract][Full Text] [Related]
2. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women.
McIntyre R; Bigler L; Dellinger T; Pfeifer M; Mannery T; Streckfus C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Dec; 88(6):687-90. PubMed ID: 10625851
[TBL] [Abstract][Full Text] [Related]
4. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
Streckfus C; Bigler L; Tucci M; Thigpen JT
Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
[TBL] [Abstract][Full Text] [Related]
5. Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men.
Streckfus C; Bigler L; Dellinger T; Dai X; Cox WJ; McArthur A; Kingman A; Thigpen JT
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Feb; 91(2):174-9. PubMed ID: 11174594
[TBL] [Abstract][Full Text] [Related]
6. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study.
Streckfus C; Bigler L
Adv Dent Res; 2005 Jun; 18(1):17-24. PubMed ID: 15998939
[TBL] [Abstract][Full Text] [Related]
7. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
[TBL] [Abstract][Full Text] [Related]
8. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
10. Correlation of serum and salivary CA125 levels in patients with breast cancer.
Agha-Hosseini F; Mirzaii-Dizgah I; Rahimi A; Seilanian-Toosi M
J Contemp Dent Pract; 2009 Nov; 10(6):E001-8. PubMed ID: 20020075
[TBL] [Abstract][Full Text] [Related]
11. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer.
Valenzuela P; Mateos S; Tello E; López-Bueno MJ; Garrido N; Gaspar MJ
Eur J Gynaecol Oncol; 2003; 24(1):60-2. PubMed ID: 12691319
[TBL] [Abstract][Full Text] [Related]
12. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: a case-control study.
Vahedi M; Abdollahzadeh S; Vaziri PB; Mortazavi H
Med Oral Patol Oral Cir Bucal; 2011 Jan; 16(1):e29-32. PubMed ID: 20711149
[TBL] [Abstract][Full Text] [Related]
14. Salivary analysis in the diagnosis and treatment of breast cancer: a role for the general dentist.
Paige SZ; Streckfus CF
Gen Dent; 2007; 55(2):156-7; quiz 158, 167-8. PubMed ID: 17333991
[TBL] [Abstract][Full Text] [Related]
15. The expression of the c-erbB-2 receptor protein in glandular salivary secretions.
Streckfus CF; Bigler L; Dellinger T; Kuhn M; Chouinard N; Dai X
J Oral Pathol Med; 2004 Nov; 33(10):595-600. PubMed ID: 15482325
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients.
Fehm T; Gebauer G; Jäger W
Breast Cancer Res Treat; 2002 Sep; 75(2):97-106. PubMed ID: 12243512
[TBL] [Abstract][Full Text] [Related]
18. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
[TBL] [Abstract][Full Text] [Related]
19. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
20. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
